Benzinga · Oct 27, 2026
Reported Oct. 26: Korro Bio Shareholder Lynx1 Capital Management Buys 79,809 Shares At An Average Price Of $11.09/Share
https://www.sec.gov/Archives/edgar/data/1703647/000090266426004286/xslF345X06/ownership.xml
KR
NASDAQ · KRRO
Korro Bio, Inc.
Healthcare · Biotechnology
$15.85
Up+$0.02 (+0.09%)
Updated Nov 4, 2026, 12:10 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 74.09M
- P/E ratio
- -0.81
- Dividend yield
- 0.00%
- 52-week range
- $8.34 – $15.90
- Volume
- 207.24K
- Avg. volume
- 526.07K
Price performance · KRRO
KRRO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
KRRO closed at $15.85 after 20 trading sessions, up 62.35% for the selected period.
- Last close
- $15.85
- Period change
- +62.35%
- Period low
- $8.49
- Period high
- $15.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $14.31 | $15.90 | $14.00 | $15.845 | 207.24K |
| Oct 30, 2026 | $13.99 | $14.55 | $13.41 | $14.315 | 130.75K |
| Oct 29, 2026 | $13.86 | $14.28 | $13.65 | $14.20 | 147.68K |
| Oct 28, 2026 | $13.18 | $14.11 | $13.04 | $13.86 | 269.31K |
| Oct 27, 2026 | $12.73 | $13.95 | $12.4101 | $13.30 | 322.66K |
| Oct 26, 2026 | $11.96 | $12.30 | $11.53 | $12.02 | 183.16K |
| Oct 23, 2026 | $12.04 | $12.49 | $11.28 | $11.98 | 237.44K |
| Oct 22, 2026 | $9.40 | $12.10 | $9.085 | $12.05 | 476.48K |
| Oct 21, 2026 | $9.47 | $9.77 | $9.22 | $9.29 | 116K |
| Oct 20, 2026 | $8.92 | $9.63 | $8.92 | $9.44 | 235.04K |
| Oct 19, 2026 | $8.58 | $8.9398 | $8.36 | $8.91 | 134.87K |
| Oct 16, 2026 | $9.32 | $9.38 | $8.45 | $8.49 | 129.73K |
| Oct 15, 2026 | $8.93 | $9.78 | $8.5301 | $9.31 | 440.18K |
| Oct 14, 2026 | $8.62 | $9.13 | $8.34 | $8.88 | 216.5K |
| Oct 13, 2026 | $9.37 | $9.39 | $8.545 | $8.81 | 264.05K |
| Oct 12, 2026 | $10.09 | $10.26 | $9.32 | $9.37 | 140.41K |
| Oct 9, 2026 | $10.60 | $10.78 | $10.125 | $10.16 | 133.51K |
| Oct 8, 2026 | $10.36 | $10.64 | $10.18 | $10.58 | 167.31K |
| Oct 7, 2026 | $9.64 | $10.64 | $9.50 | $10.49 | 157K |
| Oct 6, 2026 | $10.20 | $10.35 | $9.47 | $9.76 | 142.62K |
Latest KRRO news
The latest Smart Investors Daily articles mentioning KRRO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KRRO research
Overview
Company profile and research snapshot.
Company profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $91.25
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| May 18, 2026 | Citigroup | Buy | — |
| Mar 13, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo · Oct 22, 2026
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver Best-in-class preclinical profile supports KRRO-111’s potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027 CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE
Benzinga · Oct 22, 2026
Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-foldKRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
